Advanced

The modified hand mobility in scleroderma test and skin involvement - A followup study

Sandqvist, Gunnel LU ; Wuttge, Dirk M. LU and Hesselstrand, Roger LU (2016) In Journal of Rheumatology 43(7). p.1356-1362
Abstract

Objective. To study the change in the modified Hand Mobility in Scleroderma (mHAMIS) test from early to advanced stages of systemic sclerosis (SSc), and the relationship between mHAMIS and skin involvement during followup. Methods. This retrospective study includes 65 patients with baseline disease duration of . 3 years who were assessed with the mHAMIS test at baseline and at 1 or 2 predefined followup points (3.1.5 yrs and 5.1.9 yrs after disease onset). Studied measures were the modified Rodnan skin score (mRSS), mRSS of the hand, serum cartilage oligomeric matrix protein, and digital vascular lesions. Results. The mHAMIS and the mRSS hand changed synchronously during the first 5 years after disease onset (rs = 0.44, p = 0.001). In... (More)

Objective. To study the change in the modified Hand Mobility in Scleroderma (mHAMIS) test from early to advanced stages of systemic sclerosis (SSc), and the relationship between mHAMIS and skin involvement during followup. Methods. This retrospective study includes 65 patients with baseline disease duration of . 3 years who were assessed with the mHAMIS test at baseline and at 1 or 2 predefined followup points (3.1.5 yrs and 5.1.9 yrs after disease onset). Studied measures were the modified Rodnan skin score (mRSS), mRSS of the hand, serum cartilage oligomeric matrix protein, and digital vascular lesions. Results. The mHAMIS and the mRSS hand changed synchronously during the first 5 years after disease onset (rs = 0.44, p = 0.001). In the group with high mHAMIS at baseline, both mHAMIS and mRSS hand improved significantly at the first followup (p <0.05), and the improvement sustained during the followup in the mRSS hand. Patients with antitopoisomerase I and anti-RNA polymerase III antibodies had significantly higher mHAMIS at baseline (p = 0.003) and at the second followup (p = 0.030) compared to patients with anticentromere antibodies. Patients with digital vascular lesions at baseline had significantly higher mHAMIS during the followup (p <0.05) compared to patients without. The mHAMIS improved significantly during the followup in patients with immunosuppressive treatment in early disease (p <0.05), but not in patients without this treatment. Conclusion. The mHAMIS reflects disease activity in fibrosis in early stages of SSc. In later stages it can be regarded as a measure of damage arising from fibrotic and vascular involvement, making it suitable as an endpoint in followup examinations.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
MODIFIED HAND MOBILITY IN SCLERODERMA TEST, SYSTEMIC SCLEROSIS
in
Journal of Rheumatology
volume
43
issue
7
pages
7 pages
publisher
J Rheumatol Publ Co
external identifiers
  • Scopus:84977275812
ISSN
0315-162X
DOI
10.3899/jrheum.151142
language
English
LU publication?
yes
id
c41c3604-e1ed-4486-96a5-fcd739371902
date added to LUP
2016-07-25 13:49:30
date last changed
2016-09-20 03:06:57
@misc{c41c3604-e1ed-4486-96a5-fcd739371902,
  abstract     = {<p>Objective. To study the change in the modified Hand Mobility in Scleroderma (mHAMIS) test from early to advanced stages of systemic sclerosis (SSc), and the relationship between mHAMIS and skin involvement during followup. Methods. This retrospective study includes 65 patients with baseline disease duration of . 3 years who were assessed with the mHAMIS test at baseline and at 1 or 2 predefined followup points (3.1.5 yrs and 5.1.9 yrs after disease onset). Studied measures were the modified Rodnan skin score (mRSS), mRSS of the hand, serum cartilage oligomeric matrix protein, and digital vascular lesions. Results. The mHAMIS and the mRSS hand changed synchronously during the first 5 years after disease onset (rs = 0.44, p = 0.001). In the group with high mHAMIS at baseline, both mHAMIS and mRSS hand improved significantly at the first followup (p &lt;0.05), and the improvement sustained during the followup in the mRSS hand. Patients with antitopoisomerase I and anti-RNA polymerase III antibodies had significantly higher mHAMIS at baseline (p = 0.003) and at the second followup (p = 0.030) compared to patients with anticentromere antibodies. Patients with digital vascular lesions at baseline had significantly higher mHAMIS during the followup (p &lt;0.05) compared to patients without. The mHAMIS improved significantly during the followup in patients with immunosuppressive treatment in early disease (p &lt;0.05), but not in patients without this treatment. Conclusion. The mHAMIS reflects disease activity in fibrosis in early stages of SSc. In later stages it can be regarded as a measure of damage arising from fibrotic and vascular involvement, making it suitable as an endpoint in followup examinations.</p>},
  author       = {Sandqvist, Gunnel and Wuttge, Dirk M. and Hesselstrand, Roger},
  issn         = {0315-162X},
  keyword      = {MODIFIED HAND MOBILITY IN SCLERODERMA TEST,SYSTEMIC SCLEROSIS},
  language     = {eng},
  month        = {07},
  number       = {7},
  pages        = {1356--1362},
  publisher    = {ARRAY(0x9456588)},
  series       = {Journal of Rheumatology},
  title        = {The modified hand mobility in scleroderma test and skin involvement - A followup study},
  url          = {http://dx.doi.org/10.3899/jrheum.151142},
  volume       = {43},
  year         = {2016},
}